|
Therapeutic Areas
NPIL will initially focus on four therapeutic areas, with specific biological targets in each area:
Oncology is NPIL’s most successful program, with the lead molecule P276 currently in Phase I/II clinical trials, which are being carried out in Canada and India. The molecular target for this drug, cyclin-dependent kinase-4 (Cdk4), belongs to a class of enzymes involved in regulation of the cell cycle; that causes enhanced proliferation in tumor cells.
More recently NPIL has started screening compounds for a new target Hypoxia Inducible Factors (HIF-a).
In Inflammation, NPIL is developing drugs that inhibit the production or release of TNF-a, a protein implicated in the pathology of degenerative diseases such as Rheumatoid Arthritis.
The Diabetes/Metabolic Syndrome program is focused on discovering drugs that promote insulin sensitization and combat insulin resistance.
In the Infectious Diseases area, NPIL is evaluating antibiotics and antifungals; that work against drug resistant pathogens and vaccines against viruses.
|
